Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma

@inproceedings{Delea2012AssociationBT,
  title={Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma},
  author={Thomas E Delea and Anne Khuu and Daniel Y. C. Heng and Tomas Haas and Denis Souli{\'e}res},
  booktitle={British Journal of Cancer},
  year={2012}
}
Background:The relationship between progression-free survival and time to progression (PFS/TTP) and overall survival (OS) has been demonstrated in a variety of solid tumours but not in metastatic renal cell carcinoma (mRCC).Methods:A systematic literature search was conducted to identify controlled trials of cytokine or targeted therapies for mRCC reporting information on treatment effects on PFS/TTP and OS for one or more comparison. The associations between treatment effects on PFS/TTP and OS… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 16 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 65 REFERENCES

Randomized Phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first - line therapy for advanced renal cell carcinoma

  • JA Sosman, E Solska, +5 authors RA Figlin
  • J Clin Oncol
  • 2012

Similar Papers

Loading similar papers…